Vijaya Diagnostic Centre Ltd logo

Vijaya Diagnostic Centre Ltd

VIJAYA NSE

Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]

AI Verdict: HOLD Confidence: 5%

Vijaya Diagnostic Centre delivers strong earnings growth (27% profit CAGR over 3 years) and enjoys unanimous analyst support with 0% sell ratings, but a PE of 77x and P/B of 13.9x leave little margin of safety. The stock has rallied 38% in 1 year, pricing in much of the growth story already.

Key Fundamentals

MicrocapHealthcare Service ProviderHealthcare Services
Market Cap
₹13,993 Cr
Volatility
Moderate
P/E Ratio
81.27
EBITDA
₹337 Cr
Return on Equity
15.59%
Debt to Equity
0.4
Book Value
₹93.02
EPS
₹12.23
52W High
₹1,427.8
52W Low
₹848

Technical Indicators

Key Insights

Weaknesses

2
  • Stock is trading at 14.1 times its book value
  • Working capital days have increased from -3.87 days to 65.1 days

Growth Rate

Revenue Growth
16.36% ↗
Net Income Growth
26.56% ↗
Cash Flow Change
22.46% ↗
ROE
-0.77% ↘
ROCE
-1.44% ↘
EBITDA Margin (Avg.)
-3.17% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
HOLD
Risk high

Vijaya Diagnostic Centre delivers strong earnings growth (27% profit CAGR over 3 years) and enjoys unanimous analyst support with 0% sell ratings, but a PE of 77x and P/B of 13.9x leave little margin of safety. The stock has rallied 38% in 1 year, pricing in much of the growth story already.

Bull Case 8
  • Compounded profit growth of 27% CAGR over 3 years demonstrates strong earnings momentum
  • Revenue growth of 21% CAGR over 3 years indicates consistent demand for diagnostic services
  • ROE of 20% last year reflects efficient capital deployment and high-quality business model
  • 75% of analysts rate it a Buy with 0% sell ratings, showing strong institutional conviction across 8 coverage analysts
  • TTM sales growth of 19% shows the business continues to scale even on a larger base
  • Stock CAGR of 40% over 3 years signals sustained market confidence and re-rating potential
  • Consistent ROE of 19-20% over 3 and 5 year periods shows structural profitability, not a one-off
  • Healthcare diagnostics is a secular growth sector in India with low penetration and rising health awareness
Bear Case 8
  • PE ratio of 77x is extremely expensive, even for a high-growth healthcare compounder
  • Price-to-book of 13.9x indicates the stock is heavily priced for perfection with no room for execution misses
  • Working capital days deteriorated sharply from -3.87 days to 65.1 days, signaling potential cash conversion issues
  • Dividend yield of only 0.15% offers negligible income support to investors at current valuations
  • TTM profit growth of 25% does not justify a 77x PE multiple, implying a PEG ratio above 3x
  • 52-week high/low data unavailable, limiting technical risk assessment for entry timing
  • 5-year profit CAGR of only 15% versus 3-year CAGR of 27% suggests recent acceleration may not be sustainable long-term
  • Market cap of Rs 13,222 Cr on a mid-cap diagnostic player leaves limited upside unless growth re-accelerates beyond 25%

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Headwinds 1
  • CFO and CTO both resign Jun 9

    CFO Ankit Shah (effective Jul 24, 2026) and CTO Sai Siva Prasad (effective Aug 08, 2026) both resigned citing personal reasons, creating a leadership vacuum in finance and technology functions simultaneously.

Positives 2
  • Singapore investor roadshow planned Jun 9

    Vijaya Diagnostic will hold a non-deal roadshow with Emkay Global in Singapore on Jun 15-16, 2026, signaling active engagement with international institutional investors.

  • New Company Secretary appointed Jun 2

    Ms. Naga Vasudha Tadepalli appointed as Company Secretary & Compliance Officer effective Jun 01, 2026, ensuring governance continuity.

Neutral 1
  • ₹16.19 Cr block trade on NSE Jun 12

    Approximately 1,28,705 shares traded in a block deal at ₹1,257.80 per share on NSE, totaling ₹16.19 crores, indicating institutional-level activity.

TL;DR: Vijaya Diagnostic faces near-term leadership uncertainty with both the CFO and CTO resigning within the same week, which is a notable risk for operational continuity. On the positive side, the company is actively courting international investors through a Singapore roadshow and has filled the Company Secretary role promptly. The block trade suggests steady institutional interest at current price levels. Investors should watch for clarity on CFO/CTO replacements in the coming weeks to assess whether the leadership churn signals deeper issues or routine transitions.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
121
121
139
133
155
156
183
169
173
188
202
205
219
Expenses
72
73
82
80
92
95
107
102
104
115
120
119
124
Operating Profit
49
48
57
52
63
61
76
67
69
74
82
86
96
OPM %
41%
40%
41%
39%
41%
39%
42%
40%
40%
39%
41%
42%
44%
Other Income
5
6
7
3
3
4
5
5
5
7
6
5
2
Interest
6
6
6
6
6
6
6
7
7
7
8
9
9
Depreciation
11
12
14
15
16
17
17
18
19
21
22
24
24
PBT
36
35
45
35
44
42
57
47
47
52
58
58
64
Tax %
24%
26%
25%
25%
23%
25%
26%
24%
26%
26%
25%
26%
25%
Net Profit
28
26
34
26
34
32
42
35
35
39
43
43
48
EPS in Rs
2.69
2.57
3.26
2.53
3.27
3.06
4.1
3.43
3.4
3.76
4.21
4.2
4.66
Figures in ₹ Crores

Profit & Loss

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
251
293
339
377
462
459
548
681
814
Expenses
171
184
206
211
259
277
327
408
477
Operating Profit
80
108
133
166
204
182
221
273
337
OPM %
32%
37%
39%
44%
44%
40%
40%
40%
41%
Other Income
7
10
15
12
13
14
19
17
21
Interest
5
14
15
15
16
21
24
27
33
Depreciation
26
40
49
50
53
62
57
71
92
PBT
55
65
83
112
147
114
159
193
233
Tax %
37%
29%
25%
24%
25%
25%
25%
26%
26%
Net Profit
35
46
63
85
111
85
120
144
173
EPS in Rs
77.44
101
138
18.64
10.76
8.29
11.61
13.94
16.81
Div. Payout %
0%
0%
0%
0%
9%
12%
9%
14%
12%
Figures in ₹ Crores

Balance Sheet

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
10
10
10
10
10
Reserves
157
203
270
354
458
535
647
785
947
Borrowings
33
146
161
141
183
248
259
320
423
Other Liabilities
39
53
46
41
62
61
66
158
127
Total Liabilities
234
406
482
541
713
853
983
1,274
1,507
Fixed Assets
119
259
272
268
370
524
742
865
1,070
CWIP
3
3
10
9
34
28
9
70
34
Investments
73
69
55
28
54
139
109
185
228
Other Assets
39
76
146
236
255
163
123
154
174
Total Assets
234
406
482
541
713
853
983
1,274
1,507
Figures in ₹ Crores

Cash Flow

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
62
91
106
130
158
165
183
224
271
Investing
-98
-90
-31
-130
-123
-110
-141
-182
-174
Financing
-8
-7
-30
-49
-31
-42
-45
-52
-69
Net Cash Flow
-44
-6
46
-49
4
13
-2
-9
27
Free Cash Flow
32
31
69
98
37
40
99
132
91
CFO/OP
103
101
98
97
97
105
98
97
96
Figures in ₹ Crores

Ratios

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
12
11
9
6
8
8
11
8
9
Inventory Days
24
20
23
17
22
13
29
21
19
Days Payable
176
196
180
142
110
172
184
143
145
Cash Conversion Cycle
-140
-165
-149
-118
-81
-152
-144
-114
-117
Working Capital Days
-41
-51
-49
-26
-34
-36
-29
-48
65
ROCE %
—
28%
23%
27%
28%
18%
20%
21%
21%

Shareholding Pattern

As of Mar 2026
Promoters 52.51%
DIIs 29.93%
FIIs 13.38%
Public 3.47%
Others 0.71%
Total 100.00%
  Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
60.00%
54.78%
54.78%
54.78%
55.04%
55.01%
55.01%
55.01%
54.98%
54.90%
54.87%
54.06%
53.93%
53.91%
53.91%
53.05%
52.63%
52.60%
52.60%
52.51%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
20.09%
20.08%
18.14%
17.54%
19.36%
19.56%
18.27%
15.10%
13.38%
DIIs
0.00%
14.09%
13.30%
12.88%
12.76%
15.28%
14.23%
13.90%
19.03%
17.99%
19.55%
20.80%
21.49%
23.46%
24.63%
23.72%
24.07%
25.34%
28.59%
29.93%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
0.00%
5.45%
3.71%
3.82%
4.00%
4.97%
5.18%
5.13%
5.03%
5.06%
4.63%
4.38%
3.98%
3.94%
3.43%
3.42%
3.24%
3.20%
3.14%
3.47%
Others
40.00%
25.68%
28.21%
28.52%
28.20%
24.74%
25.58%
25.96%
20.96%
22.05%
20.95%
0.67%
0.52%
0.55%
0.49%
0.45%
0.50%
0.59%
0.57%
0.71%
No. of Shareholders
7
2,34,724
82,139
79,021
77,229
76,985
79,059
76,532
73,850
72,795
66,204
66,724
62,415
62,258
60,952
66,891
62,115
58,994
57,784
62,946

Documents

Frequently Asked Questions about Vijaya Diagnostic Centre Ltd

What does Vijaya Diagnostic Centre Ltd do?
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 d...
Where is Vijaya Diagnostic Centre Ltd (VIJAYA) listed?
Vijaya Diagnostic Centre Ltd is listed on the Indian stock exchanges. It is listed on NSE: VIJAYA and BSE: 543350. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Vijaya Diagnostic Centre Ltd belong to?
Vijaya Diagnostic Centre Ltd operates in the Healthcare sector within the Healthcare Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Vijaya Diagnostic Centre Ltd?
Vijaya Diagnostic Centre Ltd has a market capitalisation of approximately ₹13992.93 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Vijaya Diagnostic Centre Ltd?
The Price-to-Earnings (PE) ratio of Vijaya Diagnostic Centre Ltd is 81.27. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Vijaya Diagnostic Centre Ltd?
Over the past 52 weeks, Vijaya Diagnostic Centre Ltd has traded between a low of ₹848 and a high of ₹1,427.8. This range helps investors understand the stock's price volatility and recent trading levels.
Does Vijaya Diagnostic Centre Ltd pay dividends?
Yes, Vijaya Diagnostic Centre Ltd has a dividend yield of 0.15%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Vijaya Diagnostic Centre Ltd?
Vijaya Diagnostic Centre Ltd has a Return on Equity (ROE) of 15.59%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Vijaya Diagnostic Centre Ltd on Tapetide?
On Tapetide, you can view Vijaya Diagnostic Centre Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]

Website vijayadiagnostic.com
Listed 2021-09-14
Face Value ₹ 1
Issued Size 10,27,24,936

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List